Scientific - International Invitations to Give Oral Presentations
Cold Spring Harbor Laboratory, Conference on Frontiers in Single Cell Genomics, Awaji, Japan, November 5-8, 2024. Single-cell transcriptomic identification of cancer-specific mutations using full-length RNA sequencing and machine learning tools.
Gordon Conference: Mammary Gland Biology, Il Ciocco, Italy, June 2-7, 2024. Session Chair - Overview of the Single Cell Transcriptomics Landscape
23rd International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, Singapore, Sept 9-12, 2023. Identification of tumor-specific single-nucleotide variants and intratumor heterogeneity in LUADs by full length scRNAseq.
Keystone Conference: Single-Cell Biology, March 17-19, 2021 (Virtual). Transcriptomic characterization of lung cancer using single-cell RNA-sequencing.
WCRG 7th Biennial International Cancer Research Conference (Virtual), Windsor Ontario, November 18, 2020. Transcriptomic characterization of lung cancer heterogeneity using scRNA-sequencing.
20th International Association for the Study of Lung Cancer (IASLC), Singapore, Aug 8-12, 2020. Transcriptomic characterization of lung cancer using single-cell RNA-sequencing. CANCELLED
Roma Tre University, Rome Italy, July 10, 2019. Leveraging gene-editing and single cell genomics for discovery of precision medicines.
Canadian Society for Molecular Biosciences, Model Systems in Cancer Research, 62nd Annual Conference, June 2-5, 2019, Montreal. Using CRISPR-Cas9 mouse model to study lung cancer.
WCRG 6th Biennial International Cancer Research Conference, Windsor Ontario, November 18, 2018. A prelude to precision medicine: the search for new biomarkers.
19th International Association for the Study of Lung Cancer (IASLC), Toronto, Sept 23-26, 2018. Loss of Tumour Suppressors is adequate and sufficient to drive lung cancer in CRISPR/Cas9 mice.
Athena Swan, United Kingdom – London England, Feb 16, 2018.
WCRG 3rd Biennial International Cancer Research Conference, Windsor Ontario, November 19, 2016. Metabolism; the intercept between tumour microenvironment and epigenetics.
Cancer Metabolism and the Tumour Microenvironment Conference, Paphos, Cyprus, Nov 9-12, 2016. Is metabolism the intercept between tumour microenvironment & epigenetic changes that support cancer?
Cold Spring Harbor Laboratory, Cancer and Metabolism, Suzhou China, Sept 19-23, 2016. Using CRISPR/Cas9 mouse models to identify metabolic changes associated with lung cancer.
IUBMB International Conference, Signalling Pathways in Development, Disease and Ageing, July 17-21, 2016, Vancouver Canada. Metabolic changes associated with the development of Alzheimer's Disease.
Metabolism and Microenvironment in Cancer Plasticity, Venice Italy, Sept 16-19, 2015. Targeting mTOR and cancer metabolism for overcoming resistance in HER2+ breast cancer.
International Conference on Metabolomics, Philadelphia, Penn., April 24-27, 2015. Targeting cancer metabolism to overcome treatment resistance in HER2-positive breast cancer.
Michigan State University, Dept. Physiology, Oct 30, 2014. Novel targeted therapies for the treatment of metabolically active breast cancer.
International Association for Breast Cancer Research (IABCR), Sydney Australia, Sept 2014. Pre-clinical analysis of novel combinatorial therapies targeting hyperactive mTOR & cancer metabolism in HER2 breast cancer.
Targeting Mitochondrial Dysfunction and Toxicity, Boston MA, March 20-22, 2014. Targeting mitochondria for the treatment of breast cancer.
Centro Unificato di Ricerca Biomedica Applicata, Alma Mater Studiorum, Bologna Italy, Nov 8, 2013. Molecular Strategies For Identifying Novel Signalling Pathways In Disease.
Institute of Biochemistry & Cell Biology, Shanghai Institutes for Biological Sciences, May 31, 2013. Multiple functions for the tumour suppressor kinase LKB1.
The 2nd North Atlantic Zebrafish Research Symposium, Halifax, NS, May 20, 2011. Combinatorial animal models for the study of human disease.
Breast Cancer Global Congress - sponsored by the U.S. Department of State & the Avon Foundation, Oct 12-Nov 3, 2008. Requested to serve as Canadian Representative in Washington (declined due to overlap with teaching responsibilities).
CNIO Cancer Conference, Signalling Upstream of mTOR, Madrid, Nov 3-5, 2008. Novel targets of LKB1.
10th World Congress on Advances in Oncology & 8th International Symposium on Molecular Medicine, Oct 2005, Greece. Understanding LKB1 signalling in cancer progression.
University of Bari, Italy, June 17, 2005. Understanding how tumour suppressor function.
Harvard, Div. Signal Transduction, March 1999. LKB1, a novel tumour suppressor kinase.
Harvard, Cell Biology, October 1998. Vav2, reorganizer of the cytoskeleton.
FASEB 1996. The Formation of sn-1,2-Diradylglycerol Following Eicosapentaenoic Ethyl Ester and Docosahexaenoic Ethyl Ester Supplementation In Vivo Is Altered.
FASEB 1995. Second Messenger DG Formation in Murine Peritoneal Macrophages is Altered Following In Vivo n-3 Fatty Acid Supplementation.
NATO Advanced Study Institute: Eicosanoids: From Biotechnology to Therapeutic Applications, Erice, Sicily, Italy, April 27 to May 7, 1995.
Scientific - National Invitations to Give Oral Presentations
13th Conference on Signalling in Normal and Cancer Cells, Banff Centre, April 23-27, 2025. Identification of novel transcriptomic variants in cancers.
The Canadian Cancer Research Conference, Halifax, NS, November 12-14, 2023. Keynote Speaker - Improving the cancer survivorship narrative by implanting artificial Intelligence along the health care continuum.
University of Saskatchewan, College of Medicine, September 29, 2022. Exploring one cell at a time.
The Canadian Cancer Research Conference, Nov 8-11, 2021 (Virtual Meeting). Keynote Speaker - Characterization of lung cancer transcriptome using single-cell RNA-sequencing.
Canadian Society for Molecular Biosciences 2020, June 8-12, 2020, Ottawa. Characterization of lung cancer heterogeneity using scRNA-sequencing. Cancelled due to COVID19.
Ryerson University, Feb 27, 2020. Applying single-cell genomic profiling for understanding heterogeneity of human diseases.
University of Ottawa, Feb 14, 2020. Understanding cancer heterogeneity to improve precision medicines.
Breast Cancer Conference Halifax, Halifax Nova Scotia, May 5, 2018. Precision Medicine: Identifying new biomarkers for the treatment of breast cancer. Dr. Marignani organized and hosted this conference.
11th Conference on Signalling in Normal and Cancer Cells, Banff Centre, April 15-19, 2018. Signalling profile of lung cancer in CRISPR/Cas9 mice lacking multiple tumour suppressors.
In Their Own Word - Jeri and David Lacks - Henrietta Lacks (HeLa), Clinical Research Association of Canada and Canadian Institute for Medical Advancement, Glenn Gould Studio, Toronto, Oct 26, 2017. HeLa in the Marignani Discovery Research Laboratory.
Brain Research Center: Neurodevelopment Cluster Conference, Halifax, Nova Scotia, Mar 11, 2016. Metabolism in the development of Alzheimer's Disease.
Microbiology and Immunology, Dalhousie University, Nov. 23, 2015. It all about the signalling.
McMaster University, Dept. Biology, Nov. 20, 2014. It's not about the sugar, it's about the energy.
Genome Atlantic: Genetics and Genomic, April 16, 2014. Sustainable Energy: More than a pipeline; a target for novel therapeutics.
Biochemistry & Molecular Biology, Dalhousie University, Jan 23, 2014. Let the Data Guide You.
University of Alberta, December 13, 2013. Novel therapeutic pre-clinical strategies for the treatment of metabolically active cancers.
Atlantic Respirology & Critical Care Conference, Halifax, Nova Scotia, Nov 2, 2013. Identification of novel therapeutic targets for lung cancer.
University of Western Ontario, April 17, 2012. Stochastic models of breast cancer.
Memorial University, March 17, 2011. High throughput screening strategies for drug discovery.
McGill University, Dec 1, 2009. Multiple functions for the tumour suppressor kinase, LKB1.
Cancer Research Symposium, Halifax, Nova Scotia, Nov 16, 2009. The Discovery of a Novel Regulator of ERα.
Atlantic Respirology & Critical Care Conference, Halifax, NS, Nov 14, 2009. The biological role of LKB1 in lung cancer.
University of Ottawa, Sept 29, 2009. Discovery of a novel regulator of estrogen receptor alpha.
London Cancer Research Laboratory, Aug 4, 2009, London, Ont. Regulation of estrogen receptor signalling by the tumour suppressor kinase LKB1.
Canadian Proteomics Society, Oct 3, 2008, Halifax, NS. Identification of novel protein partners for the tumour suppressor kinase LKB1 by mass spectrometry and reverse chemical genetics.
Dalhousie University, Dept. Anatomy and Neurobiology, Mar 28, 2008. LKB1 Emergent Properties.
York University, Nov. 27, 2006. Novel LKB1 substrates identified by reverse chemical genetics.
University of Windsor, November 17, 2006. Loss of LKB1 leads to cell cycle progression.
CIHR Group in Matrix Dynamics, U. of Toronto, Feb. 2006. Identification of LKB1 pathways.
University of Western Ontario, Dept. Biochemistry, Sept-2004. The multi-tasking tumour suppressor kinase LKB1.
Cancer Research Symposium, Halifax, Nova Scotia, Nov-2003. Mechanisms of Cancer Progression.
University of Alberta, Department of Cell Biology, July 2002. The tumour suppressor kinase LKB1.
